Business Wire

ADVA

21.9.2021 09:02:50 CEST | Business Wire | Press release

Share
RedIRIS taps ADVA and SIA to upgrade national research network

ADVA (FSE: ADV) and SIA, Indra’s cybersecurity company, today announced that RedIRIS is deploying ADVA’s technology to create a robust, high-capacity research and education network (NREN). The new long-haul backbone infrastructure connects universities and research facilities across Spain, enabling educators and scientists to share huge data sets and harness bandwidth-intensive applications. Built on the ADVA FSP 3000 and monitored by the ADVA ALM fiber assurance solution, the network carries services at speeds up to 200Gbit/s. Featuring ADVA’s ROADM technology and QuadFlex line cards, the open solution has given RedIRIS an easy way to migrate from legacy technology to flexible, high-performance connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005058/en/

“Our new transport system empowers Spain’s scientists and academics to work together on national and international projects under optimum conditions. With flexible coherent wavelengths up to 200Gbit/s, it provides secure, highly reliable access to everything from video conferencing tools to high-performance remote computing facilities,” said Esther Robles, head of communications networks, RedIRIS. “ADVA’s open FSP 3000 technology enabled a smooth and painless transition from our existing transport infrastructure. With its modular design, it also provides massive scale, giving us the freedom to easily expand and evolve our network to meet future needs.”

Connecting more than 80 points of presence and over 500 institutions, RedIRIS’s new backbone network includes long-haul single-span submarine links to Spain’s Balearic Islands and the city of Melilla, as well as connections to the Canary Islands, the Canarian Institute of Astrophysics and its observatories. For flexibility and high spectral efficiency, the solution features ADVA’s flexgrid multi-degree ROADMs, enabling high-speed coherent and high-baud-rate transport. Through ADVA’s MicroMux™ technology, the new infrastructure also supports a seamless mix of 10Gbit/s and 100Gbit/s Ethernet client ports without any footprint increase. This optimizes space efficiency and ensures no stranded bandwidth. The network upgrade also involved the deployment of a solid and thorough migration plan by SIA, a leading Indra company in cybersecurity and ADVA’s Select partner.

“RedIRIS’s long-haul infrastructure is now one of Europe’s most advanced NRENs. It will enable researchers and teachers in Spain to leverage a new breed of data-intensive applications and collaborate in new ways using innovative video conferencing and augmented reality tools,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our open and scalable technology efficiently bridges the gap between the legacy needs and the future demand of RedIRIS’s users. Its unique client port flexibility supports a mix of 10Gbit/s and 100Gbit/s Ethernet services without the need for additional hardware. With our open optical layer, RedIRIS is also free to tackle rising demands in the future by expanding to higher baud rates and more complex modulation schemes.”

“For the design and deployment of a complex project like this, it has been key to walk hand in hand with our client RedIRIS, to perfectly understand its requirements and choose the right professionals with the knowledge and capacity to migrate to a new network that meets the organization’s present and future needs for a wide range of services. The project allows RedIRIS to carry encoded critical services that assure a greater level of cybersecurity with no latency,” stated Alejandro Díez, director, digital risk, SIA. “This deployment gives RedIRIS’s users in the research and scientific community an extremely powerful tool for high-quality collaboration and global connectivity. It also prepares Spain’s NREN for the key challenges of the future as it looks to connect more schools, universities, research centers, global libraries, smart cities and IoT. RedIRIS will operate as a critical infrastructure and will assure an immediate communication service with any other geographic point of the network, with robust processes and higher cybersecurity.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Indra

Indra is one of the leading global technology and consulting companies and the technological partner for core business operations of its customers world-wide. It is a world-leader in providing proprietary solutions in specific segments in Transport and Defense markets, and a leading firm in Digital Transformation and Information Technologies in Spain and Latin America through its affiliate Minsait. Its business model is based on a comprehensive range of proprietary products, with a high-value focus and with a high innovation component. In the 2020 financial year, Indra achieved revenue of €3.043 billion, near 48,000 employees, a local presence in 46 countries and business operations in over 140 countries. www.indracompany.com

About SIA

SIA is the Indra company leading the cybersecurity sector in Spain and Portugal, both in terms of turnover and expert talent, with more than 1,200 specialists. Its value proposition is based on the specific responses it offers organizations to meet the challenges and threats posed by the four forces of digitalization: regulatory pressure, connected infrastructures, the transformation of IT architectures and the growing digital interaction of people; responses articulated through a set of specific measures and plans to minimize risk and maximize the protection of their businesses. Being a member of the Indra Group, one of the leading global technology and consultancy companies with business operations in 140 countries, provides SIA with a profound knowledge of the industries as well as a solid worldwide presence. Further information at www.sia.es .

About RedIRIS

RedIRIS is the Spanish academic and research network that provides advanced communication services to the scientific community and national universities. It is funded by the Ministry of Science and Innovation and is included in the Ministry’s map of Special Scientific and Technological Facilities (ICTS). It is managed by the Public Corporate Entity Red.es, which reports to the Ministry of Economic Affairs and Digital Transformation. RedIRIS has over 500 affiliated institutions, mainly universities and public research centres, which join this community by signing an affiliation agreement. www.rediris.es

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye